Los puntos clave no están disponibles para este artículo en este momento.
At 13 months, the new-generation zotarolimus-eluting stent was found to be noninferior to the everolimus-eluting stent in a population of patients who had minimal exclusion criteria. (ClinicalTrials.gov number, NCT00617084.)
Serruys et al. (Thu,) studied this question.